228 related articles for article (PubMed ID: 27613464)
1. Major allergen content consistency of SQ house dust mite sublingual immunotherapy tablets and relevance across geographic regions.
Nolte H; Plunkett G; Grosch K; Larsen JN; Lund K; Bollen M
Ann Allergy Asthma Immunol; 2016 Sep; 117(3):298-303. PubMed ID: 27613464
[TBL] [Abstract][Full Text] [Related]
2. Bioavailability of House Dust Mite Allergens in Sublingual Allergy Tablets Is Highly Dependent on the Formulation.
Ohashi-Doi K; Kito H; Du W; Nakazawa H; Ipsen H; Gudmann P; Lund K
Int Arch Allergy Immunol; 2017; 174(1):26-34. PubMed ID: 28950271
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis.
Okubo K; Masuyama K; Imai T; Okamiya K; Stage BS; Seitzberg D; Konno A
J Allergy Clin Immunol; 2017 Jun; 139(6):1840-1848.e10. PubMed ID: 27864024
[TBL] [Abstract][Full Text] [Related]
4. Fractionation of Source Materials Leads to a High Reproducibility of the SQ House Dust Mite SLIT-Tablets.
Henmar H; Frisenette SM; Grosch K; Nielsen K; Smith G; Sønderkær S; Larsen JN
Int Arch Allergy Immunol; 2016; 169(1):23-32. PubMed ID: 26954940
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial.
Virchow JC; Backer V; Kuna P; Prieto L; Nolte H; Villesen HH; Ljørring C; Riis B; de Blay F
JAMA; 2016 Apr; 315(16):1715-25. PubMed ID: 27115376
[TBL] [Abstract][Full Text] [Related]
6. The Effective Allergenic Reactivity of House Dust Mite Sublingual Immunotherapy Tablets Is Determined by Tablet Formulation.
Kito H; Du W; Nakazawa H; Lund K; Ohashi-Doi K
Biol Pharm Bull; 2019; 42(6):1030-1033. PubMed ID: 31155578
[TBL] [Abstract][Full Text] [Related]
7. Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites.
Maloney J; Prenner BM; Bernstein DI; Lu S; Gawchik S; Berman G; Kaur A; Li Z; Nolte H
Ann Allergy Asthma Immunol; 2016 Jan; 116(1):59-65. PubMed ID: 26553448
[TBL] [Abstract][Full Text] [Related]
8. Molecular reactivity profiling upon immunotherapy with a 300 IR sublingual house dust mite tablet reveals marked humoral changes towards major allergens.
Potapova E; Bordas-Le Floch V; Schlederer T; Vrtala S; Huang HJ; Canonica GW; Valenta R; Matricardi PM; Mascarell L
Allergy; 2022 Oct; 77(10):3084-3095. PubMed ID: 35474582
[TBL] [Abstract][Full Text] [Related]
9. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial.
Demoly P; Emminger W; Rehm D; Backer V; Tommerup L; Kleine-Tebbe J
J Allergy Clin Immunol; 2016 Feb; 137(2):444-451.e8. PubMed ID: 26292778
[TBL] [Abstract][Full Text] [Related]
10. SQ house dust mite sublingual immunotherapy tablet subgroup efficacy and local application site reaction duration.
Bernstein DI; Kleine-Tebbe J; Nelson HS; Bardelas JA; Sussman GL; Lu S; Rehm D; Svanholm Fogh B; Nolte H
Ann Allergy Asthma Immunol; 2018 Jul; 121(1):105-110. PubMed ID: 29656145
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial.
Nolte H; Bernstein DI; Nelson HS; Kleine-Tebbe J; Sussman GL; Seitzberg D; Rehm D; Kaur A; Li Z; Lu S
J Allergy Clin Immunol; 2016 Dec; 138(6):1631-1638. PubMed ID: 27521719
[TBL] [Abstract][Full Text] [Related]
12. Clinical benefits of treatment with SQ house dust mite sublingual tablet in house dust mite allergic rhinitis.
Demoly P; Kleine-Tebbe J; Rehm D
Allergy; 2017 Oct; 72(10):1576-1578. PubMed ID: 28273339
[TBL] [Abstract][Full Text] [Related]
13. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
Calderon MA; Casale TB; Nelson HS; Demoly P
J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects of a house dust mite sublingual immunotherapy tablet in an environmental exposure chamber trial.
Zieglmayer P; Nolte H; Nelson HS; Bernstein DI; Kaur A; Jacobi H; Lemell P; Schmutz R; Zieglmayer R; Horak F
Ann Allergy Asthma Immunol; 2016 Dec; 117(6):690-696.e1. PubMed ID: 27979028
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the Allergenic Potency of House Dust Extract and House Dust Mite Allergen Extract for Subcutaneous Allergen Immunotherapy.
Du W; Fukano C; Yonemoto M; Matsuoka T; Masuyama K; Ohashi-Doi K
Biol Pharm Bull; 2019; 42(4):601-606. PubMed ID: 30930419
[TBL] [Abstract][Full Text] [Related]
16. Japanese Society of Allergology task force report on standardization of house dust mite allergen vaccines - secondary publication.
Takai T; Okamoto Y; Okubo K; Nagata M; Sakaguchi M; Fukutomi Y; Saito A; Yasueda H; Masuyama K
Allergol Int; 2015 Apr; 64(2):181-6. PubMed ID: 25838095
[TBL] [Abstract][Full Text] [Related]
17. The SQ House Dust Mite SLIT-Tablet Is Well Tolerated in Patients with House Dust Mite Respiratory Allergic Disease.
Emminger W; Hernández MD; Cardona V; Smeenk F; Fogh BS; Calderon MA; de Blay F; Backer V
Int Arch Allergy Immunol; 2017; 174(1):35-44. PubMed ID: 28950268
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet in Japanese children.
Masuyama K; Okamoto Y; Okamiya K; Azuma R; Fujinami T; Riis B; Ohashi-Doi K; Natsui K; Imai T; Okubo K
Allergy; 2018 Dec; 73(12):2352-2363. PubMed ID: 30043449
[TBL] [Abstract][Full Text] [Related]
19. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial.
Mosbech H; Deckelmann R; de Blay F; Pastorello EA; Trebas-Pietras E; Andres LP; Malcus I; Ljørring C; Canonica GW
J Allergy Clin Immunol; 2014 Sep; 134(3):568-575.e7. PubMed ID: 24797423
[TBL] [Abstract][Full Text] [Related]
20. Variation in allergen content in sublingual allergen immunotherapy with house dust mites.
Moreno Benítez F; Espinazo Romeu M; Letrán Camacho A; Mas S; García-Cózar FJ; Tabar AI
Allergy; 2015 Nov; 70(11):1413-20. PubMed ID: 26185961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
